Minimally invasive treatment modalities for life-threatening haemoptysis in patients unresponsive to medical interventions and/or in patients deemed functionally inoperable are limited. We describe the implantation of endobronchial valves in a patient with recurrent haemoptysis, which presents both a novel indication for the use of these devices and a novel intervention for haemoptysis. Our patient is a 30-year-old male who developed bilateral upper lobe aspergillomata following previous pulmonary tuberculosis. The patient had a history of multiple hospitalisations for life-threating haemoptysis despite repeated bronchial artery embolisations. He was deemed to be inoperable given the bilateral nature of his disease and very poor pulmonary reserves. We proceeded to identify the segments involved with the aid of computed tomography reconstruction and implanted 3 endobronchial valves. Our patient remained haemoptysis free for 6 months and experienced no stent-related complications. Moreover, he was subsequently employed as a manual labourer and showed significant improvements in his functional capacity. Endobronchial valves may therefore represent a viable medium-term treatment option as a blockade device in patients unresponsive to medical interventions and/or in patients deemed functionally inoperable. Prospective studies are indicated to better delineate the role of endobronchial valves in this setting.

Keywords:
Bronchiectasis, Endobronchial valves, Haemoptysis
1.
van den Heuvel MM, Els Z, Koegelenberg CF, Naidu KM, Bolliger CT, Diacon AH: Risk factors for recurrence of haemoptysis following bronchial artery embolisation for life-threatening haemoptysis. Int J Tuberc Lung Dis 2007;11:909-914.
2.
Osaki S, Nakanishi Y, Wataya H, Takayama K, Inoue K, Takaki Y, Murayama S, Hara N: Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration 2000;67:412-416.
3.
Gross AM, Diacon AH, van den Heuvel MM, Janse van Rensburg J, Harris D, Bolliger CT: Management of life-threatening haemoptysis in an area of high tuberculosis incidence. Int J Tuberc Lung Dis 2009;13:875-880.
4.
von Groote-Bidlingmaier F, Koegelenberg CF, Bolliger CT: Functional evaluation before lung resection. Clin Chest Med 2011;32:773-782.
5.
Freitag L, Tekolf E, Stamatis G, Montag M, Greschuchna D: Three years' experience with a new balloon catheter for the management of haemoptysis. Eur Respir J 1994;7:2033-2037.
6.
Sakr L, Dutau H: Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration 2010;80:38-58.
7.
Dutau H, Palot A, Haas A, Decamps I, Durieux O: Endobronchial embolization with a silicone spigot as a temporary treatment for massive haemoptysis: a new bronchoscopic approach of the disease. Respiration 2006;73:830-832.
8.
Springmeyer SC, Bolliger CT, Waddell TK, Gonzalez X, Wood DE: Treatment of heterogeneous emphysema using the spiration IBV valves. Thorac Surg Clin 2009;19:247-253.
9.
Wood DE, McKenna RJ Jr, Yusen RD, Sterman DH, Ost DE, Springmeyer SC, Gonzalez HX, Mulligan MS, Gildea T, Houck WV, Machuzak M, Mehta AC: A multicenter trial of an intrabronchial valve for treatment of severe emphysema. J Thorac Cardiovasc Surg 2007;133:65-73.
10.
Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM, Polkey MI: Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 2005;171:453-460.
11.
Feller-Kopman D, Bechara R, Garland R, Ernst A, Ashiku S: Use of a removable endobronchial valve for the treatment of bronchopleural fistula. Chest 2006;130:273-275.
12.
Dooms CA, De Leyn PR, Yserbyt J, Decaluwe H, Ninane V: Endobronchial valves for persistent postoperative pulmonary air leak: accurate monitoring and functional implications. Respiration 2012;84:329-233.
13.
Edmondstone WM, Nanson EM, Woodcock AA, Millard FJ, Hetzel MR: Life-threatening haemoptysis controlled by laser photocoagulation. Thorax 1983;38:788-789.
14.
Keller CA, Hinerman R, Singh A, Alvarez F: The use of endoscopic argon plasma coagulation in airway complications after solid organ transplantation. Chest 2001;119:1968-1975.
15.
Homasson JP: Endobronchial electrocautery. Semin Respir Crit Care 1997;18:535-543.
16.
Wong LT, Lillquist YP, Culham G, DeJong BP, Davidson AG: Treatment of recurrent hemoptysis in a child with cystic fibrosis by repeated bronchial artery embolizations and long-term tranexamic acid. Pediatr Pulmonol 1996;22:275-279.
17.
Brandes JC, Schmidt E, Yung R: Occlusive endobronchial stent placement as a novel management approach to massive hemoptysis from lung cancer. J Thorac Oncol 2008;3:1071-1072.
18.
Valipour A, Kreuzer A, Koller H, Koessler W, Burghuber OC: Bronchoscopy-guided topical hemostatic tamponade therapy for the management of life-threatening hemoptysis. Chest 2005;127:2113-2118.
19.
Reisz G: Topical hemostatic tamponade: another tool in the treatment of massive hemoptysis. Chest 2005;127:1888-1889.
20.
Bhattacharyya P, Dutta A, Samanta AN, Chowdhury SR: New procedure: bronchoscopic endobronchial sealing; a new mode of managing hemoptysis. Chest 2002;121:2066-2069.
21.
Gasparini S, Zuccatosta L, Bonifazi M, Bolliger CT: Bronchoscopic treatment of emphysema: state of the art. Respiration 2012;84:250-263.
22.
Sciurba FC, Ernst A, Herth FJF, Strange C, Criner GJ, Marquette CH, Kovitz KL, Chiacchierini RP, Goldin J, McLennan G: A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010;363:1233-1244.
23.
Herth FJF, Noppen M, Valipour A, Leroy S, Vergnon JM, Ficker JH, Egan JJ, Gasparini S, Agusti C, Holmes-Higgin D, Ernst A: Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. Eur Respir J 2012;39:1334-1342.
24.
Gompelmann D, Eberhardt R, Herth FJ: Collateral ventilation. Respiration 2013;85:515-520.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.